Wegovy 7.2mg: What the New Higher Dose Means for You
A stronger option is now available in the UK. Here's what you need to know.
Wegovy has already helped thousands of adults across the UK achieve meaningful, sustained weight loss. But for some patients, the standard maintenance dose of 2.4mg per week has not delivered the full results they were hoping for. That changes with the arrival of the new 7.2mg dose, a higher-strength option now approved by the MHRA for use in adults living with obesity.
This is not simply a bigger number on a pen. It represents a genuinely new chapter in how semaglutide-based treatment can be used, and for the right patients, it could make a significant difference.
What is the Wegovy 7.2mg dose?
The side effect profile of Wegovy 7.2mg is broadly similar to lower doses, though gastrointestinal effects were slightly more common at the higher dose.
Common Wegovy 7.2mg side effects include:
Nausea, constipation, or loose stools reported by approximately 71% of patients on 7.2mg in the STEP UP trial, compared to 61% at the 2.4mg dose. The vast majority were mild to moderate and resolved over time.
Dysaesthesia, an altered skin sensation described as tingling, burning, or heightened sensitivity, was reported in around one in five patients on the 7.2mg dose. Most cases were mild and resolved during treatment. This appears more specific to the higher semaglutide dose and is not prominently reported with tirzepatide (Mounjaro).
If side effects are significant or persistent at 7.2mg, your clinician may recommend reducing back to the 2.4mg dose while symptoms settle. You do not need to discontinue treatment entirely.
Seek medical attention promptly if you experience sudden vision changes, severe abdominal pain, or signs of an allergic reaction. Full prescribing information is available.
What does the clinical evidence show?
The STEP UP phase 3b trial, published in The Lancet Diabetes and Endocrinology in late 2025, is the most comprehensive evidence available. The trial followed over 1,400 adults across 72 weeks and compared the 7.2mg dose directly against the existing 2.4mg dose and a placebo.
The results were clear:
Average body weight reduction of 18.7% with 7.2mg, compared to 15.6% with 2.4mg
Nearly half of patients (47.7%) on the higher dose lost 20% or more of their body weight
Almost a third (31.2%) achieved weight loss of 25% or greater, a figure that was virtually zero in the placebo group
To put that in context: someone starting at 120kg could expect to lose approximately 22kg on the higher dose, compared to around 19kg on the standard dose. That additional reduction can be clinically significant, particularly for patients with weight-related conditions such as type 2 diabetes, high blood pressure, or joint problems.
The dosing schedule explained
One of the most important things to understand about Wegovy 7.2mg is that it is not where treatment begins. Semaglutide requires a gradual dose escalation to allow the body to adjust and to minimise the risk of side effects, particularly gastrointestinal ones.
The standard escalation schedule, follows this pattern:
Weeks 1 to 4: 0.25mg once weekly
Weeks 5 to 8: 0.5mg once weekly
Weeks 9 to 12: 1mg once weekly
Weeks 13 to 16: 1.7mg once weekly
Week 17 onwards: 2.4mg once weekly (standard maintenance dose)
After a minimum of 4 weeks at 2.4mg: 7.2mg once weekly (for eligible patients with obesity)
The move to 7.2mg is therefore not automatic. It is considered on an individual basis for patients who have been on the 2.4mg maintenance dose for at least four weeks and have not yet achieved sufficient weight loss. If gastrointestinal side effects are a concern at any stage, your clinician may recommend staying at a lower dose for longer before escalating.
Wegovy is injected subcutaneously, meaning just beneath the skin, in the abdomen, thigh, or upper arm. The injection can be taken at any time of day, with or without food, and the day of the week can be changed if needed, provided at least 72 hours have passed since the last dose.
Is the 7.2mg dose right for you?
This is the question worth taking seriously, rather than assuming bigger is always better.
The 7.2mg dose is designed for patients who have already reached the 2.4mg maintenance dose and are not achieving their target weight loss goals. It is not a starting point. Like all Wegovy doses, treatment begins at 0.25mg per week and escalates gradually over several months to reduce the risk of side effects, so if you are currently on a lower dose, you would not move straight to 7.2mg.
It is also worth knowing that the side effect profile at the higher dose is broadly similar to the lower doses, though gastrointestinal effects were slightly more common. Around 71% of patients in the STEP UP trial reported digestive symptoms such as nausea, constipation or loose stools, compared to 61% at the standard dose. The vast majority of these were mild to moderate and settled with time. Notably, a higher proportion of patients on 7.2mg also reported dysaesthesia, a skin sensation described as tingling, burning or heightened sensitivity, affecting around one in five participants. Most cases were mild and resolved during treatment.
As with any prescription medication, whether this dose is appropriate for you depends on your individual health profile, current progress, and any conditions that may affect suitability. The patient information leaflet contains a full list of contraindications and side effects.
Who should not take the Wegovy 7.2mg dose?
Wegovy is not suitable for everyone, and the higher dose carries the same contraindications as the lower doses. You should not take Wegovy in any form if you:
Have a personal or family history of medullary thyroid carcinoma (MTC)
Have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Have had a serious allergic reaction to semaglutide or any of the other ingredients in the formulation
Are pregnant, planning to become pregnant, or breastfeeding. Wegovy should be discontinued at least two months before a planned pregnancy due to its long half-life
Have end-stage renal disease
Have a personal history of pancreatitis, as semaglutide has not been studied in this group and should be used with particular caution
The 7.2mg dose specifically is only licenced for adults with obesity, defined as a BMI of 30 kg/m² or above. It is not approved for patients using Wegovy solely for cardiovascular risk reduction or for overweight patients in the BMI 27 to 29.9 range.
Additionally, patients with a history of gastroparesis, a condition affecting stomach emptying, should discuss this with their clinician before starting or escalating treatment, as semaglutide can worsen symptoms in this group.
If you are taking other medications, particularly insulin or sulphonylureas for diabetes, your prescriber will need to review your doses before starting Wegovy, as the combination can increase the risk of hypoglycaemia.
Will everyone achieve the same results on Wegovy 7.2mg?
The clinical trial data is encouraging, but it is worth being straightforward about something: weight loss outcomes vary from person to person, and the averages reported in trials do not reflect what every individual will experience.
Several factors can influence how effective treatment is for you, including:
Your baseline metabolic rate and body composition
How closely you follow a reduced-calorie diet and exercise programme alongside treatment
Your level of physical activity day to day
How consistently you take your injections and adhere to the dosing schedule
Any underlying health conditions, particularly those affecting the heart, kidneys, or hormonal system
This is precisely why clinical oversight throughout treatment matters. Progress is reviewed regularly so that your clinician can assess whether the current dose is working, whether escalation is appropriate, or whether any adjustments are needed. Weight loss treatment is not a one-size-fits-all process, and the most effective approach is one that is tailored to your circumstances rather than simply following what worked for someone else.
If you are not seeing the results you expected, that is a conversation worth having with your prescriber rather than a reason to stop treatment altogether.
Is it available now in the UK?
Yes. The MHRA approved the single-dose 7.2mg Wegovy pen in April 2026, following an earlier January 2026 authorisation of the same dose delivered via three consecutive 2.4mg injections. The dedicated single-pen format is the more straightforward option and is now the standard way to access this dose.
Availability through private providers is expanding. As with all GLP-1 treatments, it is only available following a proper clinical assessment.
-
No. You cannot move directly from Mounjaro to the highest Wegovy dose. If switching between treatments, your clinician will need to assess the safest way to transition, which will typically involve starting at a lower Wegovy dose and escalating from there.
-
Not at present. NHS access to Wegovy is being rolled out gradually through specialist weight management services, and the 7.2mg dose has not yet been appraised by NICE for routine NHS use. This may change in time, but for now it remains a private treatment option.
-
The 7.2mg dose comes in a dedicated single-dose pre-filled pen. The injection takes approximately five to ten seconds and should be pressed firmly against the skin until the yellow indicator bar has stopped moving. It can be injected into the abdomen, thigh, or upper arm.
-
If side effects are significant or persistent, your clinician may recommend reducing back to the 2.4mg dose until symptoms improve. You do not need to discontinue treatment entirely. However, if you experience sudden vision changes, severe abdominal pain, or signs of an allergic reaction, you should seek medical attention promptly.
-
Yes. Wegovy at any dose is intended to be used alongside a reduced-calorie diet and increased physical activity. It is not a standalone solution, and the clinical trials that established its efficacy were all conducted within this combined lifestyle framework.
Next steps
If you are currently on Wegovy and wondering whether the 7.2mg dose could be right for you, or if you are considering starting treatment for the first time, the best starting point is a consultation with one of our clinicians. We can review your progress, discuss your goals, and help you understand what is appropriate for your situation.
